Why is the Avita Medical share price rocketing 24% today?

This healthcare share is ending the week on a very positive note. But why?

| More on:
Vanadium Resources share price person riding rocket indicating share price increase

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Avita Medical Inc (ASX: AVH) share price is catching the eye on Friday.

In morning trade, the regenerative medicine company's shares are up 24% to $3.96.

Why is the Avita Medical share price rocketing?

Investors have been picking up Avita Medical's shares this morning after it released its third quarter update and revealed strong top line growth.

Here's a summary of how it performed for the three months ended 30 September:

  • Commercial revenue up 51% to US$13.5 million
  • Gross margin of 84.5% for the quarter
  • Operating expenses up 48% to US$21 million
  • Net loss widened 55% to US$8.7 million
  • Cash on hand of US$60.1 million

Despite its sizeable loss, management believes the regenerative medicine company is well-positioned and has sufficient cash to meet its profitability goals. This could explain the strong rise in the Avita Medical share price today.

This should be supported by the Recell Go product, which management appears confident will be granted US FDA approval next year.

The company's chief executive officer, Jim Corbett, commented:

We continue to execute our growth strategy, paving the way to profitability. We are diligently working through supplemental in-house testing to support the FDA's review of our PMA supplement for RECELL GO. Once complete, we expect to submit a response to the FDA's open questions on February 28, 2024. Under the Breakthrough Device program, we anticipate FDA approval on May 30, 2024, which positions us for a launch the following day.

This sentiment was echoed by its chief financial officer, David O'Toole, he adds:

We have achieved significant commercial revenue growth rates for the last three quarters of 40%, 42% and 51%, respectively, over the same periods in the previous year. Further, we remain confident that our cash reserves position us to achieve our goals and reach profitability in 2025.

Looking ahead, the company expects its strong top-line growth to continue. It is guiding to fourth-quarter commercial revenue growth of 64% to 73% over the prior corresponding period.

Following today's gain, the Avita Medical share price is now up 100% in 2023.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Avita Medical. The Motley Fool Australia has recommended Avita Medical. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX healthcare stock is jumping 7% on US FDA approval news

This share is giving its shareholders an early Christmas present.

Read more »

A senior pharmacist talks to a customer at the counter in a shop
Healthcare Shares

Is it too late to buy Sigma shares to cash in on the Chemist Warehouse deal?

Can investors still make healthy returns with this stock?

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why the Mesoblast share price is diving 18% after an FDA win

Investors are sending the Mesoblast share price tumbling on Friday. But why?

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Guess which ASX healthcare stock is jumping 12% on Wednesday

This shares is rocketing this morning. But why? Let's find out.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Healthcare Shares

Here is the dividend forecast to 2029 for CSL shares

Can this blue-chip giant provide healthy dividend income?

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

The best ASX 200 healthcare stocks to buy in 2025

These shares could give your portfolio a healthy boost next year according to Bell Potter.

Read more »

In the lab at work, the mature adult woman and young adult man smile as they review the results of their successful experimentation.
Healthcare Shares

ASX 300 healthcare stock lifts off on promising new results

Up 28% in a year, the ASX healthcare stock is leaping higher on Thursday.

Read more »